Related references
Note: Only part of the references are listed.Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC
Zhengbo Song et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b plus NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
Josephina Sampson et al.
CANCERS (2022)
Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
Esther Conde et al.
JOURNAL OF CLINICAL PATHOLOGY (2022)
EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling
Jiwei Shen et al.
CELLULAR SIGNALLING (2022)
Downregulation of PD-L1 and HLA-I in non-small cell lung cancer with ALK fusion
Di Mu et al.
THORACIC CANCER (2022)
EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity
Kellie Lucken et al.
MOLECULAR CANCER RESEARCH (2022)
Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation
Josephina Sampson et al.
EMBO REPORTS (2021)
Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
Jordi Codony-Servat et al.
TRANSLATIONAL ONCOLOGY (2021)
Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance
Di Liu et al.
LUNG CANCER (2021)
Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
Long Liang et al.
ONCOTARGETS AND THERAPY (2021)
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules
Asmin Tulpule et al.
CELL (2021)
Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis
Zhen Qin et al.
CELL DISCOVERY (2021)
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
Brion W. Murray et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Genomic and evolutionary classification of lung cancer in never smokers
Tongwu Zhang et al.
NATURE GENETICS (2021)
EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors
Kei Kunimasa et al.
CANCER GENETICS (2021)
A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients
Xue Du et al.
THORACIC CANCER (2021)
EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation
Ying Li et al.
BMC PULMONARY MEDICINE (2021)
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
Li-Chung Chiu et al.
VACCINES (2021)
LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis
Meiling Zhang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature
Ullas Batra et al.
CLINICAL LUNG CANCER (2020)
Current radiotherapy techniques in NSCLC: challenges and potential solutions
Niccolo Giaj-Levra et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7
Laura O'Regan et al.
JOURNAL OF CELL SCIENCE (2020)
Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
Noriko Hirai et al.
FRONTIERS IN ONCOLOGY (2020)
Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition
Athanasios R. Paliouras et al.
EMBO MOLECULAR MEDICINE (2020)
Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
Kyoung-Ho Pyo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
Annelisa M. Cornel et al.
CANCERS (2020)
ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer
Kathrin Fleschutz et al.
ANTICANCER RESEARCH (2020)
Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells
Chenxi Zeng et al.
LUNG CANCER (2020)
A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer
Xinyan Xu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
Runsen Jin et al.
CANCER BIOLOGY & MEDICINE (2020)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Mitotic phosphorylation by NEK6 and NEK7 reduces the microtubule affinity of EML4 to promote chromosome congression
Rozita Adib et al.
SCIENCE SIGNALING (2019)
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizonib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
Karim Rihawi et al.
TRANSLATIONAL ONCOLOGY (2019)
Global Epidemiology of Lung Cancer
Julie A. Barta et al.
ANNALS OF GLOBAL HEALTH (2019)
Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review)
Biaoxue Rong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer
Petros Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations
Christina Alidousty et al.
JOURNAL OF PATHOLOGY (2018)
Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics
Sean P. Cornillie et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2018)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
Ying Dai et al.
RADIATION ONCOLOGY (2018)
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Luis A. Carvajal et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
lincROR influences the stemness and crizotinib resistance in EML-ALK+ non-small-cell lung cancer cells
Yonghua Yang et al.
ONCOTARGETS AND THERAPY (2018)
Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system
Siwen Li et al.
THERANOSTICS (2018)
ALK-rearrangement in non-small-cell lung cancer (NSCLC)
Xue Du et al.
THORACIC CANCER (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant
Peng Song et al.
THORACIC CANCER (2018)
Examining EML4-ALK variants in the clinical setting: the next frontier?
Malini Patel et al.
JOURNAL OF THORACIC DISEASE (2018)
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
C. G. Woo et al.
ANNALS OF ONCOLOGY (2017)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
Masayoshi Miyawaki et al.
MOLECULAR CANCER RESEARCH (2017)
Heat shock protein antagonists in early stage clinical trials for NSCLC
Lizza E. L. Hendriks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer
Ryohei Katayama
PHARMACOLOGY & THERAPEUTICS (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Sarah R. Sabir et al.
CANCERS (2017)
Lung Cancer: Understanding its Molecular Pathology and the 2015 WHO Classification
Kentaro Inamura
FRONTIERS IN ONCOLOGY (2017)
Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer
Graciela Cruz-Rico et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Long Noncoding RNA and Cancer: A New Paradigm
Arunoday Bhan et al.
CANCER RESEARCH (2017)
Activation of EGFR Bypass Signaling by TGF alpha Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
Tetsuo Tani et al.
MOLECULAR CANCER THERAPEUTICS (2016)
EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
Arjan Gower et al.
MOLECULAR ONCOLOGY (2016)
Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
Shaodong Hong et al.
ONCOIMMUNOLOGY (2016)
Crizotinib resistance: implications for therapeutic strategies
I. Dagogo-Jack et al.
ANNALS OF ONCOLOGY (2016)
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
Richard Bayliss et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer
Tatsuya Yoshida et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N. Gettinger et al.
LANCET ONCOLOGY (2016)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim et al.
LANCET ONCOLOGY (2016)
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2016)
ALK F1174V mutation confers sensitivity while ALK 11171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
Sai-Hong Ou et al.
LUNG CANCER (2016)
A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib
Sandeep Kodityal et al.
LUNG CANCER (2016)
CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
Rong An et al.
ONCOTARGET (2016)
Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain
Mark W. Richards et al.
BIOCHEMICAL JOURNAL (2015)
Anaplastic lymphoma kinase: Role in cancer and therapy perspective
Zhihong Zhao et al.
CANCER BIOLOGY & THERAPY (2015)
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
Valsamo K. Anagnostou et al.
CLINICAL CANCER RESEARCH (2015)
Cellular uptake and in vivo distribution of polyhistidine peptides
Takashi Iwasaki et al.
JOURNAL OF CONTROLLED RELEASE (2015)
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic et al.
NATURE MEDICINE (2015)
Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer
Ying Dai et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
Hideko Isozaki et al.
CANCERS (2015)
Immunohistochemistry, Fluorescence in Situ Hybridization, and Reverse Transcription-Polymerase Chain Reaction for the Detection of Anaplastic Lymphoma Kinase Gene Rearrangements in Patients With Non-Small Cell Lung Cancer Potential Advantages and Methodologic Pitfalls
Irina Demidova et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2014)
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nicholas Kwiatkowski et al.
NATURE (2014)
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly et al.
NATURE MEDICINE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain
Mark W. Richards et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer
Lin Yang et al.
TUMOR BIOLOGY (2014)
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
A. T. Shaw et al.
ANNALS OF ONCOLOGY (2013)
Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
Renato Franco et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK
Yunguang Sun et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Overexpression of CRKL Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Cancer
Yan Wang et al.
MOLECULAR CARCINOGENESIS (2013)
50-Year Trends in Smoking-Related Mortality in the United States
Michael J. Thun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded Tissues
Yun-Gang Zhang et al.
PLOS ONE (2013)
Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan
Yi-Cheng Wu et al.
PLOS ONE (2013)
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2013)
Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Jim Sang et al.
CANCER DISCOVERY (2013)
Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells
J. Tanizaki et al.
BRITISH JOURNAL OF CANCER (2012)
Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
Tadaaki Yamada et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
Junko Tanizaki et al.
CLINICAL CANCER RESEARCH (2012)
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Targeting Anaplastic Lymphoma Kinase in Lung Cancer
Alice T. Shaw et al.
CLINICAL CANCER RESEARCH (2011)
Anaplastic lymphoma kinase in human cancer
Antonella Barreca et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2011)
Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
Francesca De Bacco et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers
Hiu Wing Cheung et al.
CANCER DISCOVERY (2011)
Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer
Heather R. Sanders et al.
CANCER GENETICS (2011)
Global Patterns of Cancer Incidence and Mortality Rates and Trends
Ahmedin Jemal et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
Zhao Chen et al.
CANCER RESEARCH (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
Young Lim Choi et al.
CANCER RESEARCH (2008)
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer
Hiroyuki Mano
CANCER SCIENCE (2008)
The international epidemiology of lung cancer - Geographical distribution and secular trends
Danny R. Youlden et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules
S. H. Houtman et al.
NEUROSCIENCE (2007)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
Share Paper
